替尔泊肽获美国食品药品监督管理局批准用于阻塞性睡眠呼吸暂停管理:对口腔保健提供者的意义
本文综述了美国食品药品监督管理局批准替尔泊肽(Zepbound;礼来)用于管理伴有阻塞性睡眠呼吸暂停的成人肥胖,并探讨其对多学科阻塞性睡眠呼吸暂停管理和口腔保健相关服务的意义。口腔保健提供者虽不处方替尔泊肽,但在通过临床筛查早期识别和转诊阻塞性睡眠呼吸暂停风险患者、提供口腔矫治器治疗及与医疗提供者协作中发挥关键作用。替尔泊肽通过促进减重减少呼吸中断并改善睡眠质量,可能影响口腔健康,包括牙周病管理、牙种植程序和正畸干预。
要点
- 2024年美国食品药品监督管理局批准替尔泊肽用于管理伴有阻塞性睡眠呼吸暂停的成人肥胖。
- 替尔泊肽通过促进减重减少呼吸中断并改善睡眠质量。
- 口腔保健提供者通过临床筛查早期识别和转诊阻塞性睡眠呼吸暂停风险患者,并提供口腔矫治器治疗。
核心结论
- 替尔泊肽通过靶向参与阻塞性睡眠呼吸暂停的代谢和炎症因素,提供了一种新的管理方法,可能影响口腔健康,包括牙周病管理、牙种植程序和正畸干预。
研究设计与样本
- 综述类:通过全面的MEDLINE检索,回顾了与阻塞性睡眠呼吸暂停和替尔泊肽相关的原创研究文章和系统综述。
主要发现
- 2024年,美国食品药品监督管理局批准替尔泊肽用于管理伴有阻塞性睡眠呼吸暂停的成人肥胖。
- 替尔泊肽通过促进减重,已被发现可减少呼吸中断并改善睡眠质量。
- 有效的阻塞性睡眠呼吸暂停管理需要多学科方法,包括生活方式调整、药物干预、口腔矫治器治疗和根据患者特定需求定制的手术选择。
- 口腔保健提供者不处方替尔泊肽,但通过临床筛查在早期识别和转诊阻塞性睡眠呼吸暂停风险患者中发挥关键作用,识别与气道阻塞相关的颅面特征,提供口腔矫治器治疗,并与医疗提供者密切合作。
关键数值与推荐
- 2024年美国食品药品监督管理局批准替尔泊肽用于管理伴有阻塞性睡眠呼吸暂停的成人肥胖。
临床怎么用
- 口腔保健提供者应考虑以患者为中心的需求以及全身健康与口腔健康之间的相互关系。
- 口腔保健提供者应通过临床筛查早期识别和转诊阻塞性睡眠呼吸暂停风险患者,识别与气道阻塞相关的颅面特征,提供口腔矫治器治疗,并与医疗提供者密切合作。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obstructive sleep apnea (OSA) is a common condition characterized by repeated airway collapse during sleep, leading to breathing interruptions. OSA increases the risk of developing hypertension, heart disease, stroke, and respiratory complications, reducing overall health and quality of life. The authors aimed to provide oral health care providers with an update on the US Food and Drug Administration-approved medication tirzepatide (Zepbound; Lilly) and its implications for multidisciplinary OSA management and oral health care-related services. TYPES OF STUDIES REVIEWED: A comprehensive MEDLINE search was conducted, and original research articles and systematic reviews related to OSA and tirzepatide were reviewed. RESULTS: A multidisciplinary approach involving lifestyle modifications, pharmaceutical interventions, oral appliance therapy, and surgical options tailored to patient-specific needs is required for effective management of OSA. In 2024, the US Food and Drug Administration approved tirzepatide for managing obesity in adults with OSA. By means of promoting weight loss, tirzepatide has been found to reduce breathing interruptions and enhance sleep quality. Although dental care providers do not prescribe tirzepatide, they play a critical role in early identification and referral of patients at risk of experiencing OSA through clinical screening. They recognize craniofacial features associated with airway obstruction, provide oral appliance therapy, and collaborate closely with health care providers. PRACTICAL IMPLICATIONS: Tirzepatide offers a novel approach to managing OSA by means of targeting metabolic and inflammatory factors that contribute to this condition. It has the potential to affect oral health, including the management of periodontal disease, dental implant procedures, and orthodontic interventions. Dental care providers should consider patient-centered needs and the interrelationship between systemic health and oral health.
引用
- Hassan MG, Hassan DG, Hassan GA, et al. Tirzepatide gains US Food and Drug Administration approval for the management of obstructive sleep apnea: Implications for oral health care providers. J Am Dent Assoc. 2025. PMID: 40569229. doi:10.1016/j.adaj.2025.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。